Pacira BioSciences Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
PCRX$36.49+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues: | ||
| Net product sales | $167,594 | $165,824 |
| Royalty revenue | 1,329 | 1,293 |
| Total revenues | 168,923 | 167,117 |
| Operating expenses: | ||
| Cost of goods sold | 34,306 | 47,416 |
| Research and development | 25,342 | 18,238 |
| Selling, general and administrative | 86,776 | 72,026 |
| Amortization of acquired intangible assets | 14,322 | 14,322 |
| Contingent consideration gains, acquisition-related expenses, restructuring and other | 6,187 | 1,903 |
| Total operating expenses | 166,933 | 153,905 |
| Income from operations | 1,990 | 13,212 |
| Other income (expense): | ||
| Interest income | 6,895 | 3,903 |
| Interest expense | (4,580) | (3,316) |
| Other, net | 4,401 | (159) |
| Total other income, net | 6,716 | 428 |
| Income before income taxes | 8,706 | 13,640 |
| Income tax expense | (3,894) | (4,661) |
| Net income | $4,812 | $8,979 |
| Net income per common share: | ||
| Basic and diluted net income per common share | $0.10 | $0.19 |
| Weighted average common shares outstanding: | ||
| Basic | 46,275 | 46,499 |
| Diluted | 46,526 | 52,193 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.